Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prostatic fibroblast reprogramming by Interleukin-30 activates prostate cancer metastasis programs.

Molecular biomedicine·2026
Same author

Early Cancer Detection: What's Going on and What's Next.

MedComm·2026
Same author

Interleukin-30 promotes melanoma spreading and triggers LAG-3 expression and T cell exhaustion.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Pazopanib-associated remodeling of platelet-immune cell crosstalk and immune suppressive platelet-derived extracellular vesicles in metastatic RCC.

Frontiers in immunology·2026
Same author

Tumor-on-chip's alliance with molecular pathology against metastatic disease.

Journal of biomedical science·2026
Same author

State of the art CRISPR-based strategies for cancer diagnostics and treatment.

Biomarker research·2024
Same journal

Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative study.

Experimental hematology & oncology·2026
Same journal

Role of methionine metabolism in cancer: recent advances in molecular mechanisms and therapeutic implications.

Experimental hematology & oncology·2026
Same journal

Advances in antibody-drug conjugates in cancer: latest updates from the 2026 AACR annual meeting.

Experimental hematology & oncology·2026
Same journal

Leveraging multimodal cancer immunotherapy to amplify the efficacy of oncolytic viruses.

Experimental hematology & oncology·2026
Same journal

Personalized chemotherapy guidance using patient-derived scaffolds from peritoneal colorectal metastases.

Experimental hematology & oncology·2026
Same journal

Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study.

Experimental hematology & oncology·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Targeting the cancer metabolism-immunity interface: update and perspectives.

Emma Di Carlo1,2

  • 1Department of Medicine and Sciences of Aging, "G. d'Annunzio" University of Chieti-Pescara, Via dei Vestini, 66100, Chieti, Italy. edicarlo@unich.it.

Experimental Hematology & Oncology
|July 3, 2026
PubMed
Summary
This summary is machine-generated.

Cancer cells manipulate tumor metabolism to evade immune responses. Targeting these metabolic pathways offers a promising strategy to restore antitumor immunity and improve cancer treatment outcomes.

Keywords:
Cancer-associated fibroblastsDiet and cancerImmune cell metabolismImmunotherapyMicrobiome and cancerOncometabolitesTherapy resistanceTumor metabolismTumor microenvironment

Related Experiment Videos

Last Updated: Jul 4, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Area of Science:

  • Oncology
  • Immunology
  • Metabolic Research

Background:

  • Cancer cells reprogram the tumor microenvironment's metabolism, creating nutrient competition and immunosuppression.
  • Immune cells like T cells and NK cells are impaired by nutrient deprivation and oncometabolites (e.g., lactate, adenosine).
  • Tumor vasculature, cancer-associated fibroblasts, diet, and microbiome further influence cancer-immunity metabolic crosstalk.

Purpose of the Study:

  • To review the mechanistic basis of cancer metabolism and immune regulation interplay.
  • To discuss how anti-cancer therapies impact metabolic and immune pathways.
  • To highlight next-generation metabolic therapies for cancer treatment.

Main Methods:

  • Review of current literature on cancer metabolism and immune interactions.
  • Analysis of metabolic reprogramming by cancer cells, immune cells, and stromal components.
  • Discussion of therapeutic strategies targeting metabolic checkpoints.

Main Results:

  • Metabolic crosstalk is a key factor in immune escape and treatment resistance.
  • Targeting metabolic pathways (e.g., glycolysis, adenosine signaling) can restore antitumor immunity.
  • Combination strategies integrating metabolic interventions with immunotherapy show synergistic effects.

Conclusions:

  • Metabolic reprogramming is central to tumor immune evasion and therapeutic resistance.
  • Targeting metabolic vulnerabilities, including novel inhibitors, presents a promising avenue for durable cancer control.
  • Overcoming metabolic barriers is crucial for enhancing immunotherapy and conventional cancer treatments.